CureVac NV (MIL:1CVAC)
€ 2.944 0.144 (5.14%) Market Cap: 682.36 Mil Enterprise Value: 167.57 Mil PE Ratio: 5.46 PB Ratio: 0.85 GF Score: 41/100

Q3 2022 CureVac NV Earnings Call Transcript

Nov 16, 2022 / 02:00PM GMT
Operator

Greetings, and welcome to CureVac Third Quarter and First 9 Months 2022 Financial Results and Business Update. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Sarah Fakih, Vice President, Corporate Communications and Investor Relations. Thank you. You may begin.

Sarah Fakih
CureVac N.V. - VP Corporate Communications & IR

Thank you. Good morning, good afternoon, and welcome to our conference call. My name is Sarah Fakih, and I'm the Vice President of Corporate Communications and Investor Relations at CureVac.

Please let me introduce today's speakers. On the call with me from CureVac are Franz-Werner Haas, the Chief Executive Officer; Ulrike Gnad-Vogt, our Interim Chief Development Officer; Ronald Plasterk, our Senior Vice President, Science and Innovation; and Pierre Kemula, Chief Financial Officer of CureVac.

Please note that this call is being webcast live and will be archived on the Events & Presentations section under Investor Relations on our website.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot